Loomis Sayles & Co. L P Has $99.61 Million Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Loomis Sayles & Co. L P decreased its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 1.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,243,267 shares of the company’s stock after selling 18,341 shares during the period. Loomis Sayles & Co. L P owned 2.38% of PROCEPT BioRobotics worth $99,610,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of PRCT. Values First Advisors Inc. bought a new stake in PROCEPT BioRobotics in the 3rd quarter valued at $27,000. Mark Sheptoff Financial Planning LLC bought a new stake in shares of PROCEPT BioRobotics in the second quarter valued at about $36,000. Quest Partners LLC boosted its position in shares of PROCEPT BioRobotics by 2,492.3% in the second quarter. Quest Partners LLC now owns 674 shares of the company’s stock valued at $41,000 after acquiring an additional 648 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of PROCEPT BioRobotics by 178.3% in the third quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company’s stock valued at $89,000 after acquiring an additional 713 shares in the last quarter. Finally, Sentry Investment Management LLC acquired a new stake in PROCEPT BioRobotics in the 3rd quarter worth about $120,000. 89.46% of the stock is owned by institutional investors.

Insider Activity at PROCEPT BioRobotics

In other news, Director Antal Rohit Desai sold 13,305 shares of the firm’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $76.37, for a total transaction of $1,016,102.85. Following the completion of the transaction, the director now owns 317,518 shares of the company’s stock, valued at approximately $24,248,849.66. This trade represents a 4.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Reza Zadno sold 288,461 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $91.00, for a total transaction of $26,249,951.00. Following the completion of the sale, the chief executive officer now directly owns 258,445 shares in the company, valued at approximately $23,518,495. This represents a 52.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 561,773 shares of company stock valued at $49,073,125 in the last 90 days. 17.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on PRCT. Piper Sandler restated an “overweight” rating and set a $75.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, October 8th. Jefferies Financial Group started coverage on shares of PROCEPT BioRobotics in a research report on Thursday, November 14th. They set a “hold” rating and a $95.00 price objective for the company. Truist Financial reissued a “buy” rating and issued a $105.00 target price (up from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. TD Cowen upped their price target on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Finally, Wells Fargo & Company lifted their price objective on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.50.

PROCEPT BioRobotics Stock Performance

PRCT stock opened at $93.60 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The firm has a 50-day moving average price of $82.41 and a 200-day moving average price of $72.53. PROCEPT BioRobotics Co. has a 12 month low of $33.45 and a 12 month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Monday, October 28th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.09. The business had revenue of $58.40 million during the quarter, compared to the consensus estimate of $53.30 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The firm’s revenue was up 66.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.51) EPS. Research analysts expect that PROCEPT BioRobotics Co. will post -1.74 EPS for the current year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).